billHR7417Event Monday, February 9, 2026Analyzed

Women’s Heart Health Expansion Act of 2026

Neutral
Impact3/10

Summary

The Women’s Heart Health Expansion Act of 2026 (HR7417) has been introduced in the House and referred to the Committee on Energy and Commerce. This bill authorizes $250,000,000 for fiscal years 2027 through 2031 to reauthorize and expand the WISEWOMAN program, focusing on preventive health services for women.

Key Takeaways

  • 1.HR7417 authorizes $250,000,000 for the WISEWOMAN program for FY2027-2031, focusing on women's preventive heart health.
  • 2.The bill is in the early stages, having been introduced and referred to the House Committee on Energy and Commerce.
  • 3.Actual funding is contingent upon future appropriations, as this bill only authorizes spending ceilings.

Market Implications

The bill's authorization of $250,000,000 for preventive health services could, if appropriated, increase demand for diagnostic screenings and health education programs within the Healthcare sector. Companies involved in providing blood pressure and cholesterol screening equipment, as well as health education materials and services, could see increased opportunities. However, at this early stage, no specific publicly traded companies are directly named or implicated as primary beneficiaries. The impact on the market is currently structural, pending further legislative action and specific funding allocations.

Full Analysis

HR7417, titled the Women’s Heart Health Expansion Act of 2026, was introduced in the House of Representatives on February 9, 2026, and subsequently referred to the House Committee on Energy and Commerce. This marks an early stage in the legislative process, indicating that the bill will undergo committee review and potential amendments before it can advance to a floor vote. The bill proposes to amend the Public Health Service Act to reauthorize the WISEWOMAN program. Specifically, it authorizes the appropriation of $250,000,000 for the period of fiscal years 2027 through 2031. These funds are intended for supplemental grants to expand preventive health services, including screenings for blood pressure and cholesterol, and health education for women. It is crucial to note that this is an authorization of funds, not an appropriation. Actual funding will depend on subsequent appropriations bills passed by Congress. Structural beneficiaries of this legislation, if enacted and funded, would primarily be healthcare providers and organizations that receive grants under section 1501 of the Public Health Service Act, as well as other entities designated by grant recipients and approved by the Secretary. These entities would be responsible for providing screenings, referrals, and follow-up services. The focus on preventive health services suggests potential benefits for diagnostic companies and health education providers, though no specific tickers can be identified at this early stage without further detail on the types of services and products that would be procured. The bill does not specify direct procurement from publicly traded companies. Given that the bill was introduced on February 9, 2026, and immediately referred to committee, it is in its initial stages. The next legislative steps would involve committee hearings, potential markups, and a committee vote. If it passes committee, it would then be eligible for a vote by the full House. Following House passage, it would need to be introduced and passed by the Senate and then signed by the President to become law. The timeline for these steps is uncertain, as many bills introduced at this stage do not advance further.

Market Impact Score

3/10
Minimal ImpactModerateMajor Market Event